Linyu J. Yang
East Branch
Chengdu, China
Chengdu, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Identification and Optimization of Pyridone Derivatives as Pan-MEK/RAF Nondegrading Molecular Glues for the Treatment of RAS-Driven Cancers.
Journal: Journal of medicinal chemistry
Published: May 07, 2026
High Responsiveness of Head and Neck Kaposiform Hemangioendothelioma Without Kasabach-Merritt Phenomenon to Sirolimus Monotherapy.
Journal: Pediatric blood & cancer
Published: May 07, 2026
Design and Synthesis of USP1 Inhibitors: Synergistic Antitumor Activity with PARP Inhibitors in Triple-Negative Breast Cancer.
Journal: Journal of medicinal chemistry
Published: April 29, 2026
Incidence, clinical characteristics and risk factors for infantile hemangioma ulceration after oral propranolol initiation: A retrospective study.
Journal: Journal of the American Academy of Dermatology
Published: January 31, 2026
Discovery, Synthesis, and Biological Evaluation of 1,3,4,5-Tetrahydro-6H-pyrano[4,3-c]isoquinolin-6-one Derivatives as Novel and Highly Selective PARP1 Inhibitors.
Journal: Journal of medicinal chemistry
Published: January 28, 2026
Spontaneous Regression of Kaposiform Hemangioendothelioma Without Kasabach-Merritt Phenomenon.
Journal: Pediatric blood & cancer
Published: January 04, 2026
Spotlight on challenges and novel methods in highly multiplexed tissue imaging-based spatial proteomics.
Journal: Journal of translational medicine
Published: December 04, 2025
Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB trial.
Journal: Therapeutic advances in hematology
Published: August 05, 2025
Identification of a ligand-binding site on tubulin mediating the tubulin-RB3 interaction.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 11, 2025
Design and Synthesis of Novel Deazapurine DNMT 1 Inhibitors with In Vivo Efficacy in DLBCL.
Journal: Journal of medicinal chemistry
Published: March 01, 2025
Preclinical and first-in-human of purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in relapsed/refractory multiple myeloma and lymphoma.
Journal: Signal transduction and targeted therapy
Published: October 02, 2024
Distribution, metabolism, and excretion of [14C] purinostat mesylate, a novel selective HDAC I/IIb inhibitor, in rats analyzed by high-performance liquid chromatography coupled with LTQ orbitrap mass spectrometry/radioactivity monitoring.
Journal: Journal of pharmaceutical and biomedical analysis
Published: July 26, 2024
Last Updated: 09/26/2026